Atrial fibrillation (AF) is the most prevalent sustained arrhythmia. Benefits of anticoagulation therapy in reducing the risk of ischemic stroke in the majority of patients with AF are well-established [1,2]. AF incidence is suggested to be increased in cancer patients and they are hypothesized to be at a higher risk of ischemic stroke [3]. The efficacy of prophylactic anticoagulation in cancer patients has lately been assessed in several studies, reporting divergent results [4,5]. In the last decade, four direct oral anticoagulants (DOACs) designed to reduce the risk of stroke and systemic embolism have been approved.
